Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 3/20 | 0.52 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27183395 | 0.80 | KCNN4 (0.57) | KCNN4KCNA3TSHRCYP19A1HTR2A | |
| SCHEMBL867672 | 0.78 | ALDH1A1 (0.41) | KCNN4TSHRCYP3A4MEN1KMT2A | |
| SCHEMBL30456862 | 0.76 | KCNN4 (0.47) | KCNN4KCNA3TSHRCYP19A1HTR2A | |
| SCHEMBL3522896 | 0.76 | KCNN4 (0.47) | KCNN4KCNA3TSHRCYP19A1HTR2A | |
| SCHEMBL1871740 | 0.76 | KCNN4 (0.47) | KCNN4KCNA3TSHRCYP19A1HTR2A | |
| SCHEMBL3522893 | 0.76 | KCNN4 (0.47) | KCNN4KCNA3TSHRCYP19A1HTR2A | |
| SCHEMBL28880786 | 0.75 | ALDH1A1 (0.39) | KCNN4TSHRCYP3A4MEN1KMT2A | |
| SCHEMBL3363605 | 0.72 | KCNN4 (0.42) | KCNN4KCNA3TSHRCYP19A1HTR2A | |
| SCHEMBL28491544 | 0.72 | KCNN4 (0.57) | KCNN4KCNA3TSHRCYP19A1HTR2A | |
| SCHEMBL3527440 | 0.72 | KCNN4 (0.43) | KCNN4KCNA3TSHRCYP19A1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709533-B2 | Imines as ion channel modulators | ICAGEN, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531573-B2 | potent, selective and safe inhibitors of the Ca2+-activated potassium channel | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-20060178346-A1 | Imines as ion channel modulators | ICAGEN, INC. (US) | 2006-08-10 | — | — | US | disclosed |
| EP-0918514-B9 | TRIARYL METHANE COMPOUNDS FOR THE TREATMENT OF CANCER, ACTINIC KERATOSIS AND KAPOSI'S SARCOMA | HARVARD COLLEGE (US) | 2006-07-05 | — | — | EP | disclosed |
| CN-1249018-C | Triaryl methane compounds for sickle cell disease | HARVARD COLLEGE (US) | 2006-04-05 | — | — | CN | disclosed |
| EP-0918514-B1 | TRIARYL METHANE COMPOUNDS FOR THE TREATMENT OF CANCER, ACTINIC KERATOSIS AND KAPOSI'S SARCOMA | HARVARD COLLEGE (US) | 2005-12-28 | — | — | EP | disclosed |
| US-20040127464-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | BRUGNARA CARLO (US) | 2004-07-01 | — | — | US | disclosed |
| US-20020119953-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | BRUGNARA CARLO (US) | 2002-08-29 | — | — | US | disclosed |
| US-6331564-B1 | TREATING DIARRHEA CAUSED BY INFLAMMATORY BOWEL DISEASE, AUTOIMMUNE DISEASES SUCH AS LUPUS, GLOMERULONEPHRITIS | ION PHARMACEUTICALS, INC. | 2001-12-18 | — | — | US | disclosed |
| EP-0918514-A4 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | HARVARD COLLEGE (US) | 2001-05-09 | — | — | EP | disclosed |
| CN-1251037-A | Triarylmethane compounds for sickle cell disease | HARVARD COLLEGE (US) | 2000-04-19 | — | — | CN | disclosed |
| US-6028103-A | Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0918514-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1997034589-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127464-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | CCNO, HPGDS, TSPO | KCNN4 18/4885KCNA3 504/4885TSHR 4062/4885 |
| US-20060178346-A1 | Imines as ion channel modulators | KCNN1, KCNN3, KCNN2 | KCNN4 4/4885KCNA3 34/4885TSHR 2605/4885 |
| US-20020119953-A1 | Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease | CCNO, HPGDS, TSPO | KCNN4 18/4885KCNA3 504/4885TSHR 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.